179 related articles for article (PubMed ID: 28591789)
21. Comparison of treatment outcomes with vancomycin alone versus combination therapy in severe Clostridium difficile infection.
Bass SN; Bauer SR; Neuner EA; Lam SW
J Hosp Infect; 2013 Sep; 85(1):22-7. PubMed ID: 23876778
[TBL] [Abstract][Full Text] [Related]
22. Risk factors for systemic vancomycin exposure following administration of oral vancomycin for the treatment of Clostridium difficile infection.
Pettit NN; DePestel DD; Fohl AL; Eyler R; Carver PL
Pharmacotherapy; 2015 Feb; 35(2):119-26. PubMed ID: 25689243
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model.
Chilton CH; Freeman J; Crowther GS; Todhunter SL; Wilcox MH
J Antimicrob Chemother; 2012 Oct; 67(10):2434-7. PubMed ID: 22723601
[TBL] [Abstract][Full Text] [Related]
24. Characterization of continued antibacterial therapy after diagnosis of hospital-onset Clostridium difficile infection: implications for antimicrobial stewardship.
Harpe SE; Inocencio TJ; Pakyz AL; Oinonen MJ; Polk RE
Pharmacotherapy; 2012 Aug; 32(8):744-54. PubMed ID: 23307522
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of vancomycin extended-dosing regimens for treatment of simulated Clostridium difficile infection within an in vitro human gut model.
Crowther GS; Chilton CH; Longshaw C; Todhunter SL; Ewin D; Vernon J; Karas A; Wilcox MH
J Antimicrob Chemother; 2016 Apr; 71(4):986-91. PubMed ID: 26755495
[TBL] [Abstract][Full Text] [Related]
26. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence.
Vardakas KZ; Polyzos KA; Patouni K; Rafailidis PI; Samonis G; Falagas ME
Int J Antimicrob Agents; 2012 Jul; 40(1):1-8. PubMed ID: 22398198
[TBL] [Abstract][Full Text] [Related]
27. Rifaximin in the treatment of recurrent Clostridium difficile infection.
Mattila E; Arkkila P; Mattila PS; Tarkka E; Tissari P; Anttila VJ
Aliment Pharmacol Ther; 2013 Jan; 37(1):122-8. PubMed ID: 23095030
[TBL] [Abstract][Full Text] [Related]
28. Clostridium difficile-associated disease treatment response depends on definition of cure.
Lawrence SJ; Dubberke ER; Johnson S; Gerding DN
Clin Infect Dis; 2007 Dec; 45(12):1648; author reply 1649-51. PubMed ID: 18190331
[No Abstract] [Full Text] [Related]
29. Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment.
Johnson S; Schriever C; Patel U; Patel T; Hecht DW; Gerding DN
Anaerobe; 2009 Dec; 15(6):290-1. PubMed ID: 19698797
[TBL] [Abstract][Full Text] [Related]
30. Vancomycin-resistant Clostridium innocuum bacteremia following oral vancomycin for Clostridium difficile infection.
Hung YP; Lin HJ; Wu CJ; Chen PL; Lee JC; Liu HC; Wu YH; Yeh FH; Tsai PJ; Ko WC
Anaerobe; 2014 Dec; 30():24-6. PubMed ID: 25102472
[TBL] [Abstract][Full Text] [Related]
31. Intracolonic administration of vancomycin for Clostridium difficile infection.
Grimm M; Rafael T
Nursing; 2014 Sep; 44(9):58-60. PubMed ID: 25140945
[No Abstract] [Full Text] [Related]
32. Impact of vancomycin faecal concentrations on clinical and microbiological outcomes in Clostridium difficile infection.
Thabit AK; Nicolau DP
Int J Antimicrob Agents; 2015 Aug; 46(2):205-8. PubMed ID: 26055927
[TBL] [Abstract][Full Text] [Related]
33. Risk estimation for recurrent Clostridium difficile infection based on clinical factors.
D'Agostino RB; Collins SH; Pencina KM; Kean Y; Gorbach S
Clin Infect Dis; 2014 May; 58(10):1386-93. PubMed ID: 24599770
[TBL] [Abstract][Full Text] [Related]
34. Fewer recurrent infections of C. difficile seen with fidaxomicin. This new class of antibiotic--the macrocycles--has a greater sustained response against re-infection than vancomycin.
Morrow T
Manag Care; 2011 Jul; 20(7):49-50. PubMed ID: 21848202
[No Abstract] [Full Text] [Related]
35. The role of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea.
Tart SB
J Pharm Pract; 2013 Oct; 26(5):488-90. PubMed ID: 23940121
[TBL] [Abstract][Full Text] [Related]
36. Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections.
Mullane K; Lee C; Bressler A; Buitrago M; Weiss K; Dabovic K; Praestgaard J; Leeds JA; Blais J; Pertel P
Antimicrob Agents Chemother; 2015 Mar; 59(3):1435-40. PubMed ID: 25534727
[TBL] [Abstract][Full Text] [Related]
37. Repeated Clostridium difficile infection after living donor liver transplantation.
Abe K; Shiba H; Furukawa K; Sakamoto T; Ishida Y; Yanaga K
Clin J Gastroenterol; 2018 Aug; 11(4):309-311. PubMed ID: 29497978
[TBL] [Abstract][Full Text] [Related]
38. Recurrent refractory Clostridium difficile colitis treated successfully with rifaximin and tigecycline: a case report and review of the literature.
El-Herte RI; Baban TA; Kanj SS
Scand J Infect Dis; 2012 Mar; 44(3):228-30. PubMed ID: 22077098
[TBL] [Abstract][Full Text] [Related]
39. Recurrence of dual-strain Clostridium difficile infection in an in vitro human gut model.
Crowther GS; Chilton CH; Todhunter SL; Nicholson S; Freeman J; Wilcox MH
J Antimicrob Chemother; 2015 Aug; 70(8):2316-21. PubMed ID: 25925596
[TBL] [Abstract][Full Text] [Related]
40. Vancomycin vs Metronidazole for Clostridium difficile infection: focus on recurrence and mortality.
Wu MA; Leidi F;
Intern Emerg Med; 2017 Sep; 12(6):871-872. PubMed ID: 28681270
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
